DE - TEST About the ALBA Study

Finding Paths for Managing the Hypersomnia Journey

You have the power to help awaken possibilities on the journey to find new ways to treat idiopathic hypersomnia (IH). By participating in clinical research, you can use your personal experience with IH to help energize the daily routine for others. See if you qualify for the ALBA Study today.

See If You May Qualify

About the ALBA Study

Finding Paths for Managing the Hypersomnia Journey

See If You May Qualify

You may be able to participate in the ALBA Study if you:

Are 18–70 years of age

Have a diagnosis of IH

Have a BMI between 16 and 38 kg/m²

If you are interested in participating, the study doctor or team will review additional study criteria with you.

Qualified participants will receive their assigned study medication (investigational drug or placebo) and study-related care at no cost. Participants may be reimbursed for travel and expenses.

See If You May Qualify

About the ALBA Study

IH can impose a significant burden on daily life. Researchers are working to identify treatment options that may help individuals with this disorder.

The ALBA Study is evaluating the safety and effectiveness of an investigational drug for IH. Participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients) for 4 weeks.

Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo. Participants will complete 7 scheduled study visits over the course of up to 17 weeks, including some overnight visits.

You can play a role in helping researchers find more ways to study and treat IH by participating in this clinical research study.

Your Participation Matters

Research has shown that certain diseases and drugs may affect people differently based on several factors, including age, sex assigned at birth, race, and ethnic background. For this reason, it is important that people from all backgrounds be involved in medical research. This can help to ensure that potential new drugs are safe and work well for all people impacted by the disease being studied.